Loading clinical trials...
Loading clinical trials...
A Phase 1, Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Ascending-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB107 in Healthy Adult Participants
Conditions
Interventions
BIIB107
Placebo
Locations
3
United States
CenExel Anaheim Clinical Trials
Anaheim, California, United States
QPS MRA (Miami Research Associates)
Miami, Florida, United States
Altasciences Clinical Research
Overland Park, Kansas, United States
Start Date
October 30, 2020
Primary Completion Date
March 5, 2024
Completion Date
March 5, 2024
Last Updated
April 15, 2024
NCT07310264
NCT06342713
NCT07472361
NCT06823947
NCT06649110
NCT07240675
Lead Sponsor
Biogen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions